On June 29, 2021 Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology that enables antibody-drug conjugates (ADCs) with best-in-class therapeutic index, reported the signing of a non-exclusive, target-specific license agreement with Innovent Biologics Inc., a leading biopharmaceutical company developing innovative medicines for the treatment of major diseases (Press release, Synaffix, JUN 29, 2021, View Source [SID1234584408]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Under the terms of the agreement, Synaffix will provide all the necessary proprietary ADC technologies including GlycoConnect, HydraSpace and one of its toxSYN linker-payloads, to enable Innovent to rapidly progress one of its antibodies as a best-in-class ADC candidate. The deal is the culmination of a successful initial proof-of-concept research period between the companies.
Upon signature, Innovent is granted the rights to deploy the above ADC technologies for one therapeutic molecule. Innovent will be responsible for the research, development, manufacturing and commercialization of the ADC product. Synaffix will closely support Innovent’s research activities and will be responsible for manufacturing components that are specifically related to its proprietary technologies.
Synaffix is eligible to receive an upfront payment, milestone payments related to certain development and sales performance achievements, as well as royalties on potential future commercial sales of the ADC product.
Dr. Yongjun Liu, President of Innovent said:
"We are excited to collaborate with Synaffix as Innovent is expanding its pipeline into the ADC space. Our collaboration with Synaffix adds a promising new ADC candidate to our preclinical pipeline through leveraging Synaffix’s validated, differentiated and innovative ADC technology platform and Innovent’s strong antibody capabilities. Based on Synaffix’s seamless partnering model, we could rapidly combine Synaffix’s ADC technologies with Innovent’s antibody, generate compelling research data and keep moving the project ahead swiftly."
Peter van de Sande, CEO of Synaffix said:
"This is the fourth commercial licensing deal that illustrates the potential of the Synaffix platform to increase the competitive position of our partners within the ADC space. Innovent is an ideal partner for Synaffix due to its strategic focus on innovative medicines and strong R&D capability for high quality biologic drugs. We look forward to working closely together on this exciting development program."
"Central to enhancing our value proposition has been the addition of multiple new proprietary linker-payloads to our ADC technology portfolio. In addition to our well-understood, clinical-stage technologies, GlycoConnect and HydraSpace, our proprietary toxSYN linker-payload platform facilitates any company with an antibody to develop its own highly-competitive ADC."